{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:59:19Z","timestamp":1790949559489,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Rituximab (RTX) and glucocorticoids are the first-line treatment for essential (EM) and connective tissue disease (CTD)-related mixed cryoglobulinemia vasculitis (CryoVas). Data on long-term outcomes of these CryoVas are lacking. We aimed to describe the prognosis of patients with EM and CTD-related CryoVas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study on patients with EM or CTD-related CryoVas in remission after RTX-based therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 63 patients with a median follow-up of 58\u2009months (IQR, 33\u201388\u2009months). Relapse rates were 23% at 1\u2009year, 42% at 2\u2009years and 71% at 5\u2009years after the initial flare. In univariate analysis, factors associated with relapse were purpura [HR, 2.2; 95% confidence interval (CI), 1.1\u20134.4; P\u2009=\u20090.02] and a previous flare of CryoVas (HR, 1.9; 95% CI, 1.0\u20133.7; P\u2009=\u20090.04). Maintenance therapy was associated with a lower risk of early relapse (HR, 0.3; 95% CI, 0.1\u20130.9; P\u2009=\u20090.03), but not of late relapse (HR, 2.0; 95% CI, 0.7\u20135.7; P\u2009=\u20090.21). In multivariable analysis, patients without purpura or previous flare remained at lower risk of relapse than those with at least one of the two (HR, 3.6; 95%CI, 1.6\u20138.2; P\u2009=\u20090.002). Maintenance regimen was associated with a lower risk of early relapse (HR, 0.3; 95% CI, 0.1\u20130.9; P\u2009=\u20090.03).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with EM and CTD-related CryoVas who received RTX as induction therapy, relapses were frequent and associated with purpura and a previous flare but were reduced with maintenance therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf324","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T07:55:18Z","timestamp":1749196518000},"page":"5665-5672","source":"Crossref","is-referenced-by-count":5,"title":["Prognosis of essential mixed cryoglobulinemia and connective tissue disease-related cryoglobulinemia after rituximab-induced remission"],"prefix":"10.1093","volume":"64","author":[{"given":"Claire","family":"Poggi","sequence":"first","affiliation":[{"name":"Univ. Lille, INSERM U995, CHU Lille, D\u00e9partement de M\u00e9decine Interne et d'Immunologie Clinique, Centre National de R\u00e9f\u00e9rence Maladies Syst\u00e9miques et Auto-Immunes Rares, European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases (ReCONNECT) , Lille,","place":["France"]},{"name":"Service de N\u00e9phrologie-M\u00e9decine Interne, Centre de Comp\u00e9tence Maladies Syst\u00e9miques et Auto-Immunes Rares , Valenciennes, CH Valenciennes,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[{"name":"Univ. Lille, INSERM U995, CHU Lille, D\u00e9partement de M\u00e9decine Interne et d'Immunologie Clinique, Centre National de R\u00e9f\u00e9rence Maladies Syst\u00e9miques et Auto-Immunes Rares, European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases (ReCONNECT) , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Karras","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie, H\u00f4pital Europ\u00e9en Georges Pompidou, Assistance Publique\u2014H\u00f4pitaux de Paris, Universit\u00e9 de Paris , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0905-1731","authenticated-orcid":false,"given":"Antoine","family":"Briantais","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, Assistance Publique\u2014H\u00f4pitaux de Marseille, CHU La Timone, Universit\u00e9 d\u2019Aix Marseille , Marseille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Ravaiau","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, CHU Angers , Angers,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Gobert","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, CH Carpentras , Carpentras,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Deroux","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, CHU Grenoble , Grenoble,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Nicolas","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, CHU Tours , Tours,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Belfeki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Sud Ile-de-France , Melun,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Fran\u00e7ois","sequence":"additional","affiliation":[{"name":"Service de Transplantation r\u00e9nale-N\u00e9phrologie, D\u00e9partement de N\u00e9phrologie, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Assistance Publique-H\u00f4pitaux de Sorbonne Universit\u00e9, INSERM UMR_S1155 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Groh","sequence":"additional","affiliation":[{"name":"Centre National de R\u00e9f\u00e9rence des Syndromes Hyper\u00e9osinophiliques (CEREO), Service de M\u00e9decine Interne, H\u00f4pital Foch , Suresnes,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8857-111X","authenticated-orcid":false,"given":"Jonathan","family":"London","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, Groupe Hospitalier Diaconesses Croix St Simon , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Campagne","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, H\u00f4pitaux Priv\u00e9s de Metz , Metz,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-S\u00e9bastien","family":"Allain","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, CH Saint-Malo , Saint-Malo,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Dernis","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie et Immunologie Clinique, CH Le Mans , Le Mans,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile-Audrey","family":"Durel","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, H\u00f4pital Edouard Herriot , Lyon,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Le Gallou","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, CHU Rennes , Rennes,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Curie","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, CH Evreux , Evreux,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Kerschen","sequence":"additional","affiliation":[{"name":"Service de Neurologie, CH Luxembourg , Luxembourg,","place":["Luxembourg"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Gensous","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne et d\u2019Immunologie Clinique, H\u00f4pital Saint-Andr\u00e9, CHU Bordeaux , Bordeaux,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-H\u00e9l\u00e8ne","family":"Reboux","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie, CH Sion , Sion, Suisse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"B\u00e9hal","sequence":"additional","affiliation":[{"name":"METRICS: Evaluation des Technologies de Sant\u00e9 et des Pratiques M\u00e9dicales, Universit\u00e9 de Lille, CHU Lille, ULR 2694 , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6612-7336","authenticated-orcid":false,"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, Centre de R\u00e9f\u00e9rence National pour les Maladies Autoimmunes et Syst\u00e9miques Rares, H\u00f4pital Cochin, AP-HP.Centre, Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]},{"name":"Universit\u00e9 Paris-Cit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Qu\u00e9m\u00e9neur","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie-M\u00e9decine Interne, Centre de Comp\u00e9tence Maladies Syst\u00e9miques et Auto-Immunes Rares , Valenciennes, CH Valenciennes,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"2025110820492437700_keaf324-B1","first-page":"1","article-title":"Cryoglobulinaemia","volume":"4","author":"Roccatello","year":"2018","journal-title":"Nat Rev Dis Primer"},{"key":"2025110820492437700_keaf324-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/BOR.0000000000000757","article-title":"Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis","volume":"33","author":"Kolopp-Sarda","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"2025110820492437700_keaf324-B3","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/0002-9343(74)90852-3","article-title":"Biologic and clinical significance of cryoglobulins: a report of 86 cases","volume":"57","author":"Brouet","year":"1974","journal-title":"Am J Med"},{"key":"2025110820492437700_keaf324-B4","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1001\/archinte.166.19.2101","article-title":"Increased risks of lymphoma and death among patients with non\u2013hepatitis c virus\u2013related mixed cryoglobulinemia","volume":"166","author":"Saadoun","year":"2006","journal-title":"Arch Intern Med"},{"key":"2025110820492437700_keaf324-B5","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.amjmed.2015.02.017","article-title":"Cryoglobulinemia vasculitis","volume":"128","author":"Cacoub","year":"2015","journal-title":"Am J Med"},{"key":"2025110820492437700_keaf324-B6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.autrev.2011.07.005","article-title":"Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature","volume":"11","author":"Ferri","year":"2011","journal-title":"Autoimmun Rev"},{"key":"2025110820492437700_keaf324-B7","doi-asserted-by":"crossref","first-page":"5996","DOI":"10.1182\/blood-2011-12-396028","article-title":"Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey","volume":"119","author":"Terrier","year":"2012","journal-title":"Blood"},{"key":"2025110820492437700_keaf324-B8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/annrheumdis-2012-201405","article-title":"Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey","volume":"72","author":"Terrier","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025110820492437700_keaf324-B9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10067-022-06391-w","article-title":"Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)","volume":"42","author":"Quartuccio","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2025110820492437700_keaf324-B10","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.autrev.2013.11.006","article-title":"Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: results from the French nationwide CryoVas survey","volume":"13","author":"Terrier","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2025110820492437700_keaf324-B11","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3899\/jrheum.100898","article-title":"Clinical spectrum, treatment, and outcome of patients with type II mixed cryoglobulinemia without evidence of hepatitis C infection","volume":"38","author":"Foessel","year":"2011","journal-title":"J Rheumatol"},{"key":"2025110820492437700_keaf324-B12","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1681\/ASN.2015020114","article-title":"Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN","volume":"27","author":"Zaidan","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2025110820492437700_keaf324-B13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/MD.0b013e3181c1750f","article-title":"Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection","volume":"88","author":"Matignon","year":"2009","journal-title":"Medicine (Baltimore)"},{"key":"2025110820492437700_keaf324-B14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.kint.2019.01.027","article-title":"Clinicopathological spectrum of renal parenchymal involvement in B-cell lymphoproliferative disorders","volume":"96","author":"Javaugue","year":"2019","journal-title":"Kidney Int"},{"key":"2025110820492437700_keaf324-B15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025110820492437700_keaf324-B16","doi-asserted-by":"crossref","first-page":"738788","DOI":"10.3389\/fimmu.2021.738788","article-title":"Rituximab immunomonitoring predicts remission in membranous nephropathy","volume":"12","author":"Teisseyre","year":"2021","journal-title":"Front Immunol"},{"key":"2025110820492437700_keaf324-B17","first-page":"84","article-title":"Efficacy of rituximab in severe and mild abdominal vasculitis in the course of mixed cryoglobulinemia","volume":"28","author":"Quartuccio","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2025110820492437700_keaf324-B18","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/rheumatology\/kel004","article-title":"Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids","volume":"45","author":"Quartuccio","year":"2006","journal-title":"Rheumatology"},{"key":"2025110820492437700_keaf324-B19","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/acr.20318","article-title":"Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2025110820492437700_keaf324-B20","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"2025110820492437700_keaf324-B21","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/rheumatology\/keaa541","article-title":"Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models","volume":"60","author":"McClure","year":"2021","journal-title":"Rheumatology"},{"key":"2025110820492437700_keaf324-B22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clim.2007.06.008","article-title":"Efficacy of low-dose rituximab for mixed cryoglobulinemia","volume":"125","author":"Visentini","year":"2007","journal-title":"Clin Immunol"},{"key":"2025110820492437700_keaf324-B23","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.autrev.2015.05.013","article-title":"Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: phase II clinical trial and systematic review","volume":"14","author":"Visentini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2025110820492437700_keaf324-B24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s10067-017-3552-6","article-title":"Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis","volume":"36","author":"Colantuono","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2025110820492437700_keaf324-B25","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1172\/JCI83840","article-title":"Rituximab does not reset defective early B cell tolerance checkpoints","volume":"126","author":"Chamberlain","year":"2016","journal-title":"J Clin Invest"},{"key":"2025110820492437700_keaf324-B26","doi-asserted-by":"crossref","first-page":"102577","DOI":"10.1016\/j.jaut.2020.102577","article-title":"Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: a pilot study","volume":"116","author":"Saadoun","year":"2021","journal-title":"J Autoimmun"},{"key":"2025110820492437700_keaf324-B27","doi-asserted-by":"crossref","first-page":"103034","DOI":"10.1016\/j.autrev.2022.103034","article-title":"Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: data from a European collaborative study and review of the literature","volume":"21","author":"Pouchelon","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2025110820492437700_keaf324-B28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"The Lancet"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf324\/63464945\/keaf324.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/11\/5665\/63464945\/keaf324.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/11\/5665\/63464945\/keaf324.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:49:33Z","timestamp":1762652973000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/11\/5665\/8160024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,10]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf324","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,10]]}}}